CTLA4 and non-small cell lung carcinoma: Recently, the CheckMate 9LA phase 3 clinical trial determined that the first line combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) with chemotherapy significantly increased overall survival in stage IV and recurrent NSCLC compared to chemotherapy alone [82].